GILEAD SCIENCES, INC.

GILD 10-K · Q4 2025
API behind this page

GILD Q4 2025 request

Playground key active
Request URL /api/financials?ticker=GILD&year=2025&quarter=4
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q4 2025 Q4 2024 YoY
Revenue 7,925 7,569 +4.7%
Show Product Lines breakouts
AmBisome 118 109 +8.3%
AmBisome · Europe 66 66 0.0%
AmBisome · Rest of World 46 36 +27.8%
AmBisome · US 5 7 -28.6%
Biktarvy 3,968 3,774 +5.1%
Biktarvy · Europe 445 399 +11.5%
Biktarvy · Rest of World 268 246 +8.9%
Biktarvy · US 3,255 3,129 +4.0%
Descovy 819 617 +32.7%
Descovy · Europe 26 25 +4.0%
Descovy · Rest of World 24 28 -14.3%
Descovy · US 768 563 +36.4%
Genvoya 380 470 -19.1%
Genvoya · Europe 34 42 -19.0%
Genvoya · Rest of World 15 18 -16.7%
Genvoya · US 331 410 -19.3%
Odefsey 310 336 -7.7%
Odefsey · Europe 62 73 -15.1%
Odefsey · Rest of World 10 11 -9.1%
Odefsey · US 239 252 -5.2%
Other 86 75 +14.7%
Other HIV 190 112 +69.6%
Other HIV · Europe 24 33 -27.3%
Other HIV · Rest of World 12 12 0.0%
Other HIV · US 154 67 +129.9%
Other Liver Disease 281 130 +116.2%
Other Liver Disease · Europe 97 54 +79.6%
Other Liver Disease · Rest of World 16 18 -11.1%
Other Liver Disease · US 169 58 +191.4%
Other · Europe 9 8 +12.5%
Other · Rest of World 26 16 +62.5%
Other · US 52 52 0.0%
Product 7,902 7,536 +4.9%
Product · Europe 1,222 1,160 +5.3%
Product · Rest of World 809 826 -2.1%
Product · US 5,873 5,550 +5.8%
Royalty, contract and other revenues 22 33 -33.3%
Royalty, contract and other revenues · Europe 14 15 -6.7%
Royalty, contract and other revenues · Rest of World 4 2 +100.0%
Royalty, contract and other revenues · US 3 16 -81.2%
Sofosbuvir/Velpatasvir 276 330 -16.4%
Sofosbuvir/Velpatasvir · Europe 65 69 -5.8%
Sofosbuvir/Velpatasvir · Rest of World 71 75 -5.3%
Sofosbuvir/Velpatasvir · US 139 185 -24.9%
Symtuza - Revenue share 133 144 -7.6%
Symtuza - Revenue share · Europe 32 29 +10.3%
Symtuza - Revenue share · Rest of World 3 3 0.0%
Symtuza - Revenue share · US 98 112 -12.5%
Tecartus 90 98 -8.2%
Tecartus · Europe 51 36 +41.7%
Tecartus · Rest of World 7 9 -22.2%
Tecartus · US 31 53 -41.5%
Total Cell Therapy 458 488 -6.1%
Total Cell Therapy · Europe 193 193 0.0%
Total Cell Therapy · Rest of World 82 82 0.0%
Total Cell Therapy · US 182 213 -14.6%
Total HIV 5,800 5,452 +6.4%
Total HIV · Europe 623 602 +3.5%
Total HIV · Rest of World 332 317 +4.7%
Total HIV · US 4,845 4,532 +6.9%
Total Liver Disease 845 719 +17.5%
Total Liver Disease · Europe 175 134 +30.6%
Total Liver Disease · Rest of World 213 194 +9.8%
Total Liver Disease · US 457 391 +16.9%
Total Oncology 841 843 -0.2%
Total Oncology · Europe 281 270 +4.1%
Total Oncology · Rest of World 127 113 +12.4%
Total Oncology · US 434 460 -5.7%
Total Other 205 184 +11.4%
Total Other · Europe 75 74 +1.4%
Total Other · Rest of World 72 52 +38.5%
Total Other · US 57 58 -1.7%
Trodelvy 384 355 +8.2%
Trodelvy · Europe 88 77 +14.3%
Trodelvy · Rest of World 45 31 +45.2%
Trodelvy · US 251 247 +1.6%
Veklury 211 338 -37.6%
Veklury · Europe 67 80 -16.2%
Veklury · Rest of World 65 150 -56.7%
Veklury · US 80 108 -25.9%
Vemlidy 287 260 +10.4%
Vemlidy · Europe 13 11 +18.2%
Vemlidy · Rest of World 125 100 +25.0%
Vemlidy · US 149 148 +0.7%
Yescarta 368 389 -5.4%
Yescarta · Europe 143 157 -8.9%
Yescarta · Rest of World 75 72 +4.2%
Yescarta · US 151 160 -5.6%
Show Geography breakouts
Europe 1,236 1,175 +5.2%
Rest of World 813 826 -1.6%
US 5,876 5,567 +5.6%
Show Equity Components breakouts
Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income -30 8 -475.0%
Cost of Revenue 1,624 1,581 +2.7%
Research And Development Expense Excluding Acquired In Process Cost 1,584 1,641 -3.5%
Research And Development Asset Acquired Other Than Through Business Combination Written Off 539 -11 +5000.0%
Impairment Of Intangible Assets Indefinitelived Excluding Goodwill 400 0 —
Selling, General & Administrative 1,794 1,907 -5.9%
Show Business Segments breakouts
Reportable Segment 1,794 1,907 -5.9%
Total Costs & Expenses 5,941 5,117 +16.1%
Operating Income 1,984 2,452 -19.1%
Interest Expense 255 249 +2.4%
Non-Operating Income (Expense) -349 35 -1097.1%
Income Before Taxes 2,078 2,167 -4.1%
Income Tax Expense (Benefit) -105 385 -127.3%
Show Equity Components breakouts
Income tax (benefit) expense · Reclassification Out Of Accumulated Other Comprehensive Income -4 1 -500.0%
Net Income 2,183 1,783 +22.4%
Show Equity Components breakouts
Retained Earnings 2,183 1,783 +22.4%
Net Income 2,183 1,783 +22.4%
EPS (Basic) 1.76 1.42 +23.9%
EPS (Diluted) 1.74 1.42 +22.5%
Wtd Avg Shares (Basic) -1 0 —
Wtd Avg Shares (Diluted) -1 8 -112.5%
Sales & Marketing (Q) — — —
Show Business Segments breakouts
Reportable Segment 1,076 1,057 +1.8%
General & Administrative (Q) — — —
Show Business Segments breakouts
Reportable Segment 718 850 -15.5%
Other Non-Operating Income (Expense) -2 -5 +60.0%
Comprehensive Income 2,186 1,842 +18.7%
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax 34 122 -72.1%

Balance Sheet

Balance Sheet
Metric Q4 2025 Q4 2024 YoY
Current Assets
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 7,564 9,991 -24.3%
Marketable Securities (Current) 68 — —
Accounts Receivable 4,913 4,420 +11.2%
Inventory 1,774 1,710 +3.7%
Show Public Utilities Inventory breakouts
Trodelvy 613 — —
Prepaid Expenses & Other Current Assets 4,024 3,052 +31.8%
Total Current Assets 18,342 19,173 -4.3%
Non-Current Assets
Property, Plant & Equipment 5,606 5,414 +3.5%
Show Geography breakouts
Non Us 631 627 +0.6%
US 4,975 4,787 +3.9%
Marketable Securities (Non-Current) 2,974 — —
Goodwill 8,314 8,314 0.0%
Deferred Tax Assets 1,964 2,378 -17.4%
Other Non-Current Assets 4,845 3,769 +28.5%
Total Assets 59,023 58,995 0.0%
Operating Lease Right-of-Use Assets 532 515 +3.3%
Intangible Assets 14,678 17,058 -14.0%
Show Finite Lived Intangible Assets By Major Class breakouts
Hepcludex [Member] 430 516 -16.7%
Intangible asset – axicabtagene ciloleucel 3,983 4,389 -9.3%
Intangible asset – sofosbuvir 2,272 2,971 -23.5%
Other Intangible Assets 428 535 -20.0%
Trodelvy 7,566 8,647 -12.5%
Other Assets
Intangible Assets Net Excluding Goodwill 16,978 19,948 -14.9%
Current Liabilities
Accounts Payable 715 833 -14.2%
Accrued Rebates 4,337 3,892 +11.4%
Debt Current 2,807 1,815 +54.7%
Other Liabilities Current 3,953 5,464 -27.7%
Total Current Liabilities 11,813 12,004 -1.6%
Current Portion of Long-Term Debt 2,807 1,815 +54.7%
Non-Current Liabilities
Long-Term Debt 22,129 24,896 -11.1%
Accrued Income Taxes Noncurrent 896 830 +8.0%
Deferred Tax Liabilities 402 724 -44.5%
Other Non-Current Liabilities 1,165 1,295 -10.0%
Long-Term Debt 24,937 26,710 -6.6%
Show Debt Instrument breakouts
1.20% Senior Unsecured Notes Due October 2027 · Senior Notes 749 748 +0.1%
1.65% Senior Unsecured Notes Due October 2030 · Senior Notes 996 995 +0.1%
2.60% Senior Unsecured Notes Due October 2040 · Senior Notes 990 989 +0.1%
2.80% Senior Unsecured Notes Due October 2050 · Senior Notes 1,480 1,479 +0.1%
2.95% Senior Unsecured Notes Due in March 2027 · Senior Notes 1,249 1,249 0.0%
3.65% Senior Unsecured Notes Due in March 2026 · Senior Notes 2,750 2,747 +0.1%
4.00% Senior Unsecured Notes Due in September 2036 · Senior Notes 744 744 0.0%
4.15% Senior Unsecured Notes Due in March 2047 · Senior Notes 1,731 1,730 +0.1%
4.50% Senior Unsecured Notes Due in February 2045 · Senior Notes 1,736 1,735 +0.1%
4.60% Senior Unsecured Notes Due in September 2035 · Senior Notes 994 994 0.0%
4.75% Senior Unsecured Notes Due in March 2046 · Senior Notes 2,225 2,224 0.0%
4.80% Senior Unsecured Notes Due in April 2044 · Senior Notes 1,738 1,738 0.0%
4.80% Senior Unsecured Notes Due in November 2029 · Senior Notes 747 746 +0.1%
5.10% Senior Unsecured Notes Due in June 2035 · Senior Notes 992 991 +0.1%
5.25% Senior Unsecured Notes Due October 2033 · Senior Notes 994 993 +0.1%
5.50% Senior Unsecured Notes Due November 2054 · Senior Notes 989 989 0.0%
5.55% Senior Unsecured Notes Due October 2053 · Senior Notes 989 988 +0.1%
5.60% Senior Unsecured Notes Due November 2064 · Senior Notes 739 738 +0.1%
5.65% Senior Unsecured Notes Due in December 2041 · Senior Notes 997 997 0.0%
Show Long-Term Debt Type breakouts
Notes Payable Other Payables 1,110 1,148 -3.3%
Senior Notes 24,000 — —
Operating Lease Liabilities 503 498 +1.0%
Stockholders' Equity
Common Stock 1 1 0.0%
Additional Paid-In Capital 8,932 7,700 +16.0%
Accumulated Other Comprehensive Income 39 132 -70.5%
Retained Earnings 13,730 11,497 +19.4%
Total Stockholders' Equity 22,703 19,330 +17.4%
Minority Interest -84 -84 0.0%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 22,618 19,246 +17.5%
Show Equity Components breakouts
Accumulated Gain Loss Net Cash Flow Hedge Parent -43 96 -144.8%
Accumulated Net Unrealized Investment Gain Loss 8 — —
Accumulated Other Comprehensive Income 39 132 -70.5%
Accumulated Translation Adjustment 74 36 +105.6%
Additional Paid In Capital 8,932 7,700 +16.0%
Common Stock 1 1 0.0%
Noncontrolling Interest -84 -84 0.0%
Retained Earnings 13,730 11,497 +19.4%
Total Liabilities & Equity 59,023 58,995 0.0%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q4 2025 YTD Q4 2024 YoY
Operating Activities
Depreciation 90 95 -5.3%
Adjustment For Amortization 597 598 -0.2%
Stock-Based Compensation 230 222 +3.6%
Deferred Income Taxes -122 -379 +67.8%
Increase Decrease In Equity Securities Fv Ni -253 126 -300.8%
Other Non-Cash Items 267 59 +352.5%
Change in Accounts Receivable 179 72 +148.6%
Change in Inventory -123 -226 +45.6%
Change in Prepaid & Other Assets -36 -146 +75.3%
Change in Accounts Payable -95 -58 -63.8%
Increase Decrease In Income Taxes -134 536 -125.0%
Increase Decrease In Accrued Liabilities -395 305 -229.5%
Net Cash from Operations 3,327 2,975 +11.8%
Investing Activities
Purchases of Investments -1,382 0 —
Proceeds From Sale Of Available For Sale Securities Debt 340 0 —
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities 23 0 —
Payments To Acquire Businesses Net Of Cash Acquired -609 -75 -712.0%
Payments To Acquire Other Investments -14 -39 +64.1%
Capital Expenditures -205 -147 -39.5%
Other Investing Activities 11 35 -68.6%
Net Cash from Investing -1,835 -225 -715.6%
Financing Activities
Proceeds From Issuance Of Common Stock 32 173 -81.5%
Share Repurchases -230 -350 +34.3%
Debt Repayments -8 -7 -14.3%
Payments Of Dividends -994 -973 -2.2%
Proceeds From Payments For Other Financing Activities -63 -47 -34.0%
Net Cash from Financing -1,263 2,260 -155.9%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 5 -55 +109.1%
Net Change in Cash 233 4,955 -95.3%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key